PHARMACOKINETICS OF ELAGOLIX, A NOVEL ORAL GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST ADMINISTERED TO FEMALE SUBJECTS WITH RENAL IMPAIRMENT.

Trial Profile

PHARMACOKINETICS OF ELAGOLIX, A NOVEL ORAL GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST ADMINISTERED TO FEMALE SUBJECTS WITH RENAL IMPAIRMENT.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2015

At a glance

  • Drugs Elagolix (Primary)
  • Indications Endometriosis; Uterine leiomyoma
  • Focus Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 10 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top